1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Anti-Infective Drug News 11 MAY 2015

Anti-Infective Drug News 11 MAY 2015

  • May 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - GSK's Shingles Vaccine To Erode Sales Of Merck's Zostavax
Industry Brief - FDA Accepts NDA Filing For AuriPro
Industry Brief - Single-Dose Dalvance Meets Primary/Secondary Endpoints In Phase III Study For ABSSSIs
Industry Brief - Arno's AR-12 Gains EU Orphan Designation In Cryptococcosis/Tularaemia
Industry Brief - Cresemba Launched In US For Invasive Aspergillosis/Mucormycosis
Industry Brief - TetraLogic Temporarily Halts Birinapant cHBV Trial
Industry Trend Analysis - Gilead/AbbVie To Eradicate Niche Commercial Opportunities In HCV
Industry Brief - Mylan Launches Sofosbuvir In India
Industry Brief - ViiV Begins Phase III Dolutegravir/Rilpivirine Combination Programme In HIV Maintenance Therapy
Industry Brief - Senate Panel Advances California Vaccination Bill After Amendment
Industry Trend Analysis - ViiV To Help GSK Weather A Tumultuous 2015
Industry Trend Analysis - Gilead Positioned To Make Key Acquisition

Table Of Contents

Anti-Infective Drug News 11 MAY 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • October 2016
  • by Grand View Research

The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to a new report by Grand View Research, Inc., HIV continues to be one ...

Anti-Infectives Market Analysis & Trends - Product (Antibacterials, Antifungals and Antivirals) - Forecast to 2025

Anti-Infectives Market Analysis & Trends - Product (Antibacterials, Antifungals and Antivirals) - Forecast to 2025

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Anti-Infectives Market is poised to grow at a CAGR of around 6.3% over the next decade to reach approximately $190.28 billion by 2025. Some of the prominent trends that the market is witnessing ...

Global and Chinese Zidovudine (CAS 30516-87-1) Industry, 2017 Market Research Report

Global and Chinese Zidovudine (CAS 30516-87-1) Industry, 2017 Market Research Report

  • $ 3000
  • Industry report
  • February 2017
  • by Prof Research

The 'Global and Chinese Zidovudine Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Zidovudine industry with a focus on the Chinese market. ...


Download Unlimited Documents from Trusted Public Sources

HIV AIDS Statistics and Antiviral Market in the US

  • February 2017
    31 pages
  • HIV AIDS  

    Antiviral  

  • United States  

View report >

HIV AIDS Statistics and HIV Antiviral Market in China

  • February 2017
    11 pages
  • HIV AIDS  

    Infectious Dise...  

    HIV Antiviral  

  • China  

    United States  

View report >

Anesthetics and Therapy Market in the US

  • February 2017
    9 pages
  • Anesthetics  

    Therapy  

  • United States  

View report >

Related Market Segments :

Antiviral
Infectious Disease

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.